Accendra Health Inc (ACH) Stock Analysis
Verdict: AVOID
Severe balance sheet distress with -$461M equity and $2.23B debt makes ACH a high-dilution or restructuring risk despite home health assets.
Investment score: 13/100
Analysis as of
Is Accendra Health Inc stock worth reviewing? The TradeMates thesis
The model sees Accendra Health as a distressed medical distributor in critical balance sheet territory. With negative net equity and $2.23B in debt, the risk of capital restructuring dominates the outlook.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 10/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
Accendra Health Inc opportunities and risks
What speaks for ACH
- Patient Direct Division Stabilization
What speaks against ACH
- Imminent Cash Burn and Liquidity Exhaustion
Frequently asked questions about Accendra Health Inc (ACH)
Is ACH stock a good investment?
The TradeMates model rates Accendra Health Inc as AVOID with an investment score of 13/100. The model sees Accendra Health as a distressed medical distributor in critical balance sheet territory. With negative net equity and $2.23B in debt, the risk of capital restructuring dominates the outlook. This is algorithmic model output, not personal investment advice.
Is ACH stock a buy?
The TradeMates model verdict for ACH is AVOID with an investment score of 13/100. Treat this as a model signal to review, not a personal buy recommendation.